ArticleFrontiers in health services2025
Health technology assessment infrastructure for emirates health services: a phased framework.
Article in Frontiers in health services, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Policy dialogue on health technology assessment in Middle East and North Africa: reporting from an HTAi initiative.International journal of technology assessment in health care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This policy brief presents a structured, phased framework to establish Health Technology Assessment (HTA) within Emirates Health Services (EHS), promoting evidence-based decision-making and optimizing healthcare delivery. The model emphasizes capacity building, stakeholder engagement, and transparency to enhance patient outcomes and ensure financial sustainability. It follows four phases: Phase 0 (strategy alignment, stakeholder mapping), Phase 1 (budget impact and disease burden analysis), Phase 2 (managed entry agreements, multi-criteria decision analysis), and Phase 3 (full HTA adoption with performance metrics). Key methodologies include budget impact modeling, cost-effectiveness, and cost-utility analysis. Evidence is drawn from registries, clinical databases, and pharmacoeconomic studies. The framework offers a scalable and sustainable roadmap for HTA in the UAE, supporting efficient technology integration, optimal resource allocation, and alignment with national priorities. However, the framework's successful implementation will depend on the availability of high-quality local data, sustained stakeholder engagement, and supportive regulatory mechanisms. Potential challenges such as resource constraints, fragmented governance, and variability in HTA maturity across the region highlight the need for flexibility and adaptive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.